Telomir Pharmaceuticals, Financials
| TELO Stock | 4.91 0.03 0.61% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.34 | 0.3259 |
|
|
The essential information of the day-to-day investment outlook for Telomir Pharmaceuticals, includes many different criteria found on its balance sheet. An individual investor should monitor Telomir Pharmaceuticals,'s cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Telomir Pharmaceuticals,.
Net Income |
|
Telomir | Select Account or Indicator |
Telomir Pharmaceuticals, Stock Summary
Telomir Pharmaceuticals, competes with Emergent Biosolutions, Neurocrine Biosciences, Teva Pharma, Haleon Plc, and Amphastar. Telomir Pharmaceuticals, is entity of United States. It is traded as Stock on NASDAQ exchange.| Foreign Associate | Canada |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 87975F104 |
| Location | Florida; U.S.A |
| Business Address | 100 SE 2nd |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | telomirpharma.com |
| Phone | 813 864 2558 |
Telomir Pharmaceuticals, Key Financial Ratios
| Return On Equity | -17.53 | ||||
| EBITDA | (11.43 M) | ||||
| Net Income | (13.07 M) | ||||
| Book Value Per Share | 0.01 X | ||||
| Market Capitalization | 146.98 M |
Telomir Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Telomir Pharmaceuticals,'s current stock value. Our valuation model uses many indicators to compare Telomir Pharmaceuticals, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Telomir Pharmaceuticals, competition to find correlations between indicators driving Telomir Pharmaceuticals,'s intrinsic value. More Info.Telomir Pharmaceuticals, Common is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Telomir Pharmaceuticals,'s Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telomir Pharmaceuticals,'s earnings, one of the primary drivers of an investment's value.Telomir Pharmaceuticals, Systematic Risk
Telomir Pharmaceuticals,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Telomir Pharmaceuticals, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fifty with a total number of output elements of eleven. The Beta measures systematic risk based on how returns on Telomir Pharmaceuticals, correlated with the market. If Beta is less than 0 Telomir Pharmaceuticals, generally moves in the opposite direction as compared to the market. If Telomir Pharmaceuticals, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Telomir Pharmaceuticals, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Telomir Pharmaceuticals, is generally in the same direction as the market. If Beta > 1 Telomir Pharmaceuticals, moves generally in the same direction as, but more than the movement of the benchmark.
Telomir Pharmaceuticals, Thematic Clasifications
Telomir Pharmaceuticals, Common is part of several thematic ideas from Computers to IT. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasTelomir Pharmaceuticals, December 18, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Telomir Pharmaceuticals, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Telomir Pharmaceuticals, Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of Telomir Pharmaceuticals, Common based on widely used predictive technical indicators. In general, we focus on analyzing Telomir Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Telomir Pharmaceuticals,'s daily price indicators and compare them against related drivers.
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 45.18 | |||
| Value At Risk | (9.07) | |||
| Potential Upside | 14.82 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telomir Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.78) | Return On Assets (2.05) | Return On Equity (17.53) |
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.